Welcome to our dedicated page for Tscan Therapeutics SEC filings (Ticker: TCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TScan Therapeutics, Inc. (TCRX) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. TScan is a clinical-stage biotechnology company listed on The Nasdaq Global Market, and its filings offer detailed insight into its T cell receptor-engineered T cell (TCR-T) therapy programs, financial condition, and corporate governance.
For TCRX, key filings include current reports on Form 8-K that describe material events such as clinical and regulatory milestones for TSC-101 in the ALLOHA™ Phase 1 heme trial, strategic prioritization of the hematologic malignancies program, pauses in solid tumor trial enrollment, and updates on in vivo engineering and autoimmunity research. Other 8-Ks address financial results, workforce changes, executive appointments, and stockholder meeting outcomes. These documents help readers understand how TScan is advancing its heme and solid tumor programs, implementing a commercial-ready manufacturing process, and managing its operating runway.
Investors can also use this page to locate annual and quarterly reports (Forms 10-K and 10-Q) when available, which typically contain comprehensive discussions of TScan’s pipeline, risk factors, and financial statements. In addition, filings related to equity compensation plans, retention programs for key executives, and stockholder votes provide visibility into compensation structures and governance practices.
Stock Titan enhances access to TCRX filings by offering real-time updates from EDGAR and AI-powered summaries that explain the significance of each document in straightforward language. Users can quickly scan for information on clinical trial plans, cash runway disclosures, strategic shifts between heme, solid tumor, and autoimmunity efforts, and other developments that shape TScan Therapeutics’ profile as a public biotechnology company.
TScan Therapeutics, Inc. reported a leadership change in its finance organization. Leiden Dworak notified the company of his decision to resign as Vice President of Finance and principal accounting officer, effective April 10, 2026, and the company stated there were no disagreements regarding its operations, policies or practices.
The Board appointed Chief Financial Officer Jason A. Amello to also serve as principal accounting officer effective April 10, 2026. The company noted that Mr. Amello will not receive additional compensation for this added role and referenced its May 14, 2025 definitive proxy statement for information on his background, contracts and related party transactions.
TScan Therapeutics, Inc. presents an in-depth annual overview of its business and pipeline. The company focuses on T cell receptor-engineered T cell (TCR-T) therapies for hematologic cancers, solid tumors and autoimmune diseases, supported by an internal GMP manufacturing facility.
Lead candidate TSC-101 targets HA-2 in AML and MDS patients undergoing allogeneic transplantation. In the Phase 1 ALLOHA trial, relapse-free and overall survival trends favored TSC-101, with 3 of 3 patients two years post-transplant showing no evidence of disease versus 1 of 4 in the control arm, and no dose-limiting toxicities observed.
The FDA has agreed on a registrational path for TSC-101, and cleared INDs for follow-on heme candidates TSC-102-A01 and TSC-102-A03. The company has paused its solid tumor Phase 1 trial to prioritize its heme program and in vivo engineering for off-the-shelf multiplex TCR-T therapies.
TScan is also advancing an autoimmune discovery program and maintains a collaboration with Amgen in Crohn’s disease, under which it has received a $30.0 million upfront payment and is eligible for over $500 million in milestones plus tiered royalties.
TScan Therapeutics reported fourth-quarter and full-year 2025 results and outlined key clinical milestones. Revenue rose to $2.6M in Q4 2025 from $0.7M a year earlier, and to $10.3M for 2025 from $2.8M in 2024, mainly from its Amgen collaboration.
R&D expenses were $20.0M for Q4 and $114.2M for 2025, while G&A expenses were $6.4M for Q4 and $32.0M for 2025. Net loss narrowed to $23.0M in Q4 2025 from $35.8M in Q4 2024 and was $129.8M for 2025 versus $127.5M in 2024.
The company highlighted positive Phase 1 ALLOHA™ heme data, FDA clearance of INDs for CD45-targeting TSC-102-A01 and TSC-102-A03, completion of Cohort C enrollment, and plans to launch a pivotal trial for TSC-101 and start a Phase 1 study for TSC-102 candidates in 2026. Cash and cash equivalents were $152.4M as of December 31, 2025, which TScan believes will fund its operating plan into the second half of 2027.
TScan Therapeutics granted Chief Financial Officer Jason Amello a stock option for 350,000 shares of voting common stock on January 20, 2026. The option has an exercise price of $1.12 per share and was awarded at no cost to the executive. Following this grant, Amello beneficially owns options for 350,000 shares.
The award vests over time: 25% of the shares vest on the one-year anniversary of January 20, 2026, with the remaining 75% vesting in equal monthly installments over the next 36 months, conditioned on his continued service with the company.
TScan Therapeutics, Inc. granted stock options to its Chief Executive Officer and director, Gavin MacBeath. On January 20, 2026, he received a stock option to purchase 1,165,000 shares of voting common stock at an exercise price of $1.12 per share. The option was granted at no cost for the derivative itself.
According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on the one-year anniversary of January 20, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months. Vesting is conditioned on his continued service to the company on each vesting date. Following this grant, MacBeath beneficially owned 1,165,000 derivative securities directly.
TScan Therapeutics, Inc. reported that officer Dworak Leiden received a stock option grant covering 100,000 shares of voting common stock on January 20, 2026. The option has an exercise price of $1.12 per share and was awarded at no cost for the derivative itself. The grant vests 25% of the shares on the one-year anniversary of January 20, 2026, with the remaining shares vesting in equal monthly installments over the next 36 months, conditioned on continued service. Following this award, the reporting person beneficially owns 100,000 derivative securities directly.
TScan Therapeutics granted its Chief Medical Officer, Louis Chrystal, a stock option covering 420,000 shares of voting common stock at an exercise price of $1.12 per share. The option was granted on January 20, 2026 and is held directly. The award vests over four years: 25% of the shares vest on the one-year anniversary of January 20, 2026, with the remaining 75% vesting in equal monthly installments over the following 36 months, conditioned on Chrystal’s continued service with the company on each vesting date.
TScan Therapeutics reported that officer Zoran Zdraveski, Chief Legal and Strategy Officer, received a grant of 350,000 stock options on January 20, 2026. These options give the right to buy TScan voting common stock at an exercise price of $1.12 per share and expire on January 20, 2036.
According to the vesting terms, 25% of the options vest on the one-year anniversary of January 20, 2026, with the remaining options vesting in equal monthly installments over the following 36 months, subject to Mr. Zdraveski’s continued service with the company. After this grant, he beneficially owns 350,000 derivative securities directly in the form of these options.
TScan Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings during the 44th Annual J.P. Morgan Healthcare Conference. The materials are provided as Exhibit 99.1 and are also available in the investor relations section of the company’s website. The presentation is being furnished under a current report on Form 8-K, meaning it is not treated as filed for liability purposes and is not automatically incorporated into other securities law filings unless specifically referenced.
TScan Therapeutics, Inc. approved a targeted retention program for key executives tied to progress in its pivotal trial of TSC-101. The Board, following the Compensation Committee’s recommendation, adopted a key employee retention program that provides cash and potential future equity-based awards under the 2021 Equity Incentive Plan.
Under this program, CEO Gavin MacBeath, Ph.D., CFO Jason A. Amello and CMO Chrystal Louis, M.D., M.P.H., will be eligible for cash awards of $399,000, $170,000 and $250,000, respectively. Half of each cash award is payable upon achievement of a milestone related to advancement of the pivotal trial of TSC-101, and the other half on the first anniversary of that milestone.
Upon achievement of the same milestone, they are also slated to receive equity awards of 1,000,000 RSUs, 270,000 RSUs and 650,000 RSUs, respectively. These RSUs are scheduled to vest 25% on the second anniversary of the milestone and 75% upon the earlier of reporting completion of the pivotal TSC-101 trial or the fourth anniversary of the grant date, subject to continued service and the terms of the plan and award agreements.